Skip to main content
. 2015 Apr 7;10(4):e0121915. doi: 10.1371/journal.pone.0121915

Fig 3. Cost-effectiveness acceptability curve for the (A) DURATION-6 clinical input and (B) Scott and colleagues’ meta-analysis clinical input analyses.

Fig 3

The figure displays the probability that the liraglutide strategy is a cost-effective alternative to the exenatide strategy over a plausible range of willingness to pay per 1% HbA1c reduction.